Gilead Sciences (Gilead Sciences) GF Value : $73.79 (As of Apr. 27, 2024)

View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-27), Gilead Sciences's share price is $65.42. Gilead Sciences's GF Value is $73.79. Therefore, Gilead Sciences's Price-to-GF-Value for today is 0.89.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Gilead Sciences is Modestly Undervalued.

Gilead Sciences (NAS:GILD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Gilead Sciences's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	65.42	/	73.79
	=	0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences GF Value Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (Gilead Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Executives

Andrew D Dickinson	officer: EVP, Chief Financial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier	officer: Chief Commercial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey	officer: Chief Medical Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson	officer: SVP, Controllership	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong	officer: SVP, Controller & CAO	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman	officer: EVP, Corporate Affairs & GC	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher	officer: EVP, Gen Counsel & Corp Sec	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters	director
Javier Rodriguez	director	601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan	director	2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson	director	C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold	director	C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711